OPKO Health, Inc. is a multinational healthcare company involved in both diagnostics and pharmaceuticals, with operations in the United States and several countries, including Ireland, Chile, Spain, Israel, and Mexico. Its Diagnostics segment includes BioReference Laboratories, which provides a range of laboratory testing services and core genetic testing, such as the 4Kscore prostate cancer test. The Pharmaceuticals segment offers products like Rayaldee, aimed at treating secondary hyperparathyroidism and vitamin D insufficiency in chronic kidney disease patients, and is developing various drugs for conditions including type 2 diabetes, obesity, and hemophilia. OPKO also focuses on creating specialty active pharmaceutical ingredients and has a portfolio that includes nutraceuticals, veterinary products, and generics. The company is committed to leveraging its expertise in discovery, development, and commercialization to explore growth opportunities and expand its geographical presence. Incorporated in 1991 and headquartered in Miami, Florida, OPKO Health continues to pursue innovations in medical treatments and diagnostics.
HealthSnap is an integrated Virtual Care Management Platform that helps healthcare organizations improve patient outcomes, reduce utilization, and diversify revenue streams. From chronic disease-agnostic Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) to AI-guided care coordination, virtual care delivery, automated care management billing, population analytics - and so much more - HealthSnap is the simplest way to manage chronic conditions remotely.
Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.
Phio Pharmaceuticals is a biotechnology company specializing in the application of RNAi therapies in immuno-oncology. Its proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies. It is a patented platform from which unique patented compounds are created to silence genes that tumors use to evade the immune system.
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
EirGen Pharma focuses on the development, registration and commercial manufacture of high potency, high barrier to entry solid dose products for the global pharmaceutical market. EirGen Pharma is fully licensed to manufacture oncology, cytotoxic, steroidal and immunosuppressant molecules in a purpose built high containment facility. The state of the art facilities can also handle the development of moisture sensitive molecules in a low humidity environment. The company has an Investigational Medicinal Products (IMP) licence for the manufacture of clinical trial materials and a Manufacturing Licence for commercial manufacturing and packaging.
Inspiro Medical Ltd. is a medical device company dedicated to the development of a global inhalation platform designed to deliver both small molecules such as corticosteroids or beta agonists; and macromolecules such as antibodies or vaccines. The Company is currently performing clinical trials with asthmatic children using Inspiromatic, its proprietary dry powder inhaler.
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Fabrus LLC was founded in 2007 as the first company in The Pfizer Incubator. The company has assembled a seasoned scientific team that has met and exceeded its milestones by establishing a unique antibody discovery platform and discovering multiple preclinical lead candidates against important cancer targets.
Vidus Ocular
Acquisition in 2008
Vidus Ocular, Inc. develops an implantable physiologic device that is designed to address the shortcomings of glaucoma treatments. It offers Aquashunt, which is a shunt to treat glaucoma, the cause of blindness in the United States. The company is based in the United States. As of May 7, 2008, Vidus Ocular, Inc. operates as a subsidiary of Opko Health, Inc.
Acuity Pharmaceuticals is a pharmaceutical company that is focused on the treatment and prevention of ophthalmic diseases. It develops treatments for age-related macular degeneration and diabetic retinopathy. The company offers Cand5, a clinical compound that is able to shut down vascular endothelial growth factor. Acuity Pharmaceuticals was acquired by OPKO Health in June 2011. Acuity Pharmaceuticals was founded in 2007 and is based in Philadelphia, Pennsylvania.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.